Xaira Therapeutics

Type: Private — well-funded stealth AI drug discovery company

Xaira Therapeutics launched in April 2024 with over $1 billion in funding — the largest debut round ever recorded in the AI drug discovery space. The company's technical lineage traces to RFdiffusion (diffusion model for de novo protein design, Baker Lab, University of Washington), and its founding team includes leadership from Genentech (Marc Tessier-Lavigne, former Genentech CSO, is involved in leadership).

Very little is publicly disclosed about Xaira's specific programs or pipeline — the company is operating in research mode. What is known:

• The scientific bet is that diffusion models conditioned on functional specifications (binding, catalysis, signal transduction) can design protein therapeutics from first principles, without relying on natural analogs or hit-to-lead campaigns
• RFdiffusion (Baker lab) is the most powerful known tool for this task as of 2025–2026
• Xaira has bolstered its leadership team and relocated headquarters as of 2025 (Drug Discovery Trends)

What to watch

• First program disclosure (expected 2026–2027)
• IND submission (no public timeline given)
• Whether RFdiffusion-designed molecules survive early preclinical validation

Confidence note

Low confidence — Xaira is intentionally opaque. Most public information is from the funding announcement. Treat as "well-funded bet on the Baker lab protein design paradigm."

Sources

• FierceBiotech: Xaira $1B launch
• FierceBiotech: Xaira R&D focus
• Drug Discovery Trends: leadership update